Delivery Order SPE2DB22D3301-SPE2DB25FY9FX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with firm fixed pricing. This is a non-set-aside delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is executing this...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on September 9, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. The contract is a firm fixed price delivery order with a ceiling value of $224,205.12 and an ultimate completion date of September 30, 2025. This award was competitively awarded with no set-aside designation. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order contract to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials valued at $46,544.00. This is a firm fixed-price delivery order with an ultimate completion date of May 28, 2025, and represents a non-competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,981.60 to AmerisourceBergen Drug Corp for GAMUNEX-C, a 40-gram/400 milliliter immunoglobulin vial. The contract, issued on August 6, 2025, carries a firm fixed price and is scheduled for completion by August 27, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a $23,272.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C (40 gram/400 ml vial), with an ultimate completion date of August 13, 2025. This is an unset-aside, competitively awarded contract that will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. As a child order under a larger contract vehicle, this delivery order represents a single transaction within AmerisourceBergen's extensive pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials, with a contract ceiling value of $2,327.20 and an ultimate completion date of September 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,178.10 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order was issued without a set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency awarded a $13,963.20 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials with a completion date of September 23, 2025. This firm fixed-price contract, issued without set-aside designation, represents a competitive award to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The delivery order is structured as a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $34,908 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 14, 2025, with performance to take place at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting AmerisourceBergen's demonstrated capability to compete in the...
- The Defense Logistics Agency awarded a $15,311.23 delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials with an ultimate completion date of June 11, 2025. This firm fixed-price delivery order represents a non-set-aside award, reflecting open competitive procurement. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY9FXDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $46,544 firm fixed-price delivery order on August 12, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. The contract is unclassified as a set-aside and has an ultimate completion date of September 3, 2025. AmerisourceBergen will perform this delivery order from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle that runs through December 2026 and enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen regularly fulfills competitive delivery orders through the DLA Medical Supply Chain. GAMUNEX-C is an immunoglobulin product used for treating immunodeficiency disorders and is part of the company's extensive portfolio of specialty medications and biologics supplied to the Defense Health Agency and other government healthcare systems. This delivery order reflects the company's ongoing role in supporting military medical readiness through the provision of specialized pharmaceutical commodities on a firm fixed-price basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.5k | 8/12/25 |